Matches in SemOpenAlex for { <https://semopenalex.org/work/W2801841898> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W2801841898 abstract "Oral administration of dual or triple therapy is very effective in chronic hepatitis C virus infection. The current study was conducted to evaluate the effectiveness and safety of daclatasvir plus sofosbuvir with or without ribavirin in treatment-naive patients with HCV genotype 4 infection. In this study, 90 naive patients with HCV genotype 4 infection were divided into 3 groups (N=30 per each group) and randomly assigned to receive orally either daclatasvir (60 mg) plus sofosbuvir (400 mg) with or without ribavirin (800-1200 mg according to the patient’s weight) daily for 12 weeks, or sofosbuvir plus ribavirin orally and daily for 24 weeks. The primary endpoint was an HCV RNA level of < 25 IU per millilitre at week 12 (sustained virologic response at week 12, SVR12). From the current study, the males received sofosbuvir plus daclatasvir had SVR12 50%, while the females within the same group achieved SVR12 57%. Males received sofosbuvir with ribavirin achieved SVR12 85% and SVR24 94.7%, while females in the same group achieved SVR12 90.9% and SVR24 98.9 %. The highest SVR12 rates (100% in both males and females) were achieved in naive patients received the triple therapy of daclatasvir plus sofosbuvir with ribavirin. The most common adverse effects were fatigue, headache, and low haemoglobin content. Only, one female patient experienced elevated serum alanine aminotransferase (ALAT) activity after the end of the treatment. No deaths or serious adverse effects resulted in case of treatment discontinuation. In conclusion, for HCV genotype 4 infection, once-daily oral dose of the triple therapy of daclatasvir plus sofosbuvir with ribavirin for 12 weeks appears to be a very good treatment option with the lowest adverse effects and the highest SVR rates." @default.
- W2801841898 created "2018-05-17" @default.
- W2801841898 creator A5022158572 @default.
- W2801841898 creator A5023994937 @default.
- W2801841898 creator A5073555065 @default.
- W2801841898 creator A5086901802 @default.
- W2801841898 date "2017-12-01" @default.
- W2801841898 modified "2023-09-27" @default.
- W2801841898 title "THE USE OF DACLATASVIR PLUS SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN IN TREATMENT-NAÏVE PATIENTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 4 INFECTION" @default.
- W2801841898 doi "https://doi.org/10.12816/0043191" @default.
- W2801841898 hasPublicationYear "2017" @default.
- W2801841898 type Work @default.
- W2801841898 sameAs 2801841898 @default.
- W2801841898 citedByCount "0" @default.
- W2801841898 crossrefType "journal-article" @default.
- W2801841898 hasAuthorship W2801841898A5022158572 @default.
- W2801841898 hasAuthorship W2801841898A5023994937 @default.
- W2801841898 hasAuthorship W2801841898A5073555065 @default.
- W2801841898 hasAuthorship W2801841898A5086901802 @default.
- W2801841898 hasConcept C126322002 @default.
- W2801841898 hasConcept C159047783 @default.
- W2801841898 hasConcept C197934379 @default.
- W2801841898 hasConcept C2522874641 @default.
- W2801841898 hasConcept C2776408679 @default.
- W2801841898 hasConcept C2776455275 @default.
- W2801841898 hasConcept C2776979040 @default.
- W2801841898 hasConcept C2778390639 @default.
- W2801841898 hasConcept C2780040827 @default.
- W2801841898 hasConcept C71924100 @default.
- W2801841898 hasConcept C90924648 @default.
- W2801841898 hasConceptScore W2801841898C126322002 @default.
- W2801841898 hasConceptScore W2801841898C159047783 @default.
- W2801841898 hasConceptScore W2801841898C197934379 @default.
- W2801841898 hasConceptScore W2801841898C2522874641 @default.
- W2801841898 hasConceptScore W2801841898C2776408679 @default.
- W2801841898 hasConceptScore W2801841898C2776455275 @default.
- W2801841898 hasConceptScore W2801841898C2776979040 @default.
- W2801841898 hasConceptScore W2801841898C2778390639 @default.
- W2801841898 hasConceptScore W2801841898C2780040827 @default.
- W2801841898 hasConceptScore W2801841898C71924100 @default.
- W2801841898 hasConceptScore W2801841898C90924648 @default.
- W2801841898 hasLocation W28018418981 @default.
- W2801841898 hasOpenAccess W2801841898 @default.
- W2801841898 hasPrimaryLocation W28018418981 @default.
- W2801841898 hasRelatedWork W1980771473 @default.
- W2801841898 hasRelatedWork W2014288897 @default.
- W2801841898 hasRelatedWork W2037648619 @default.
- W2801841898 hasRelatedWork W2060087636 @default.
- W2801841898 hasRelatedWork W2126689013 @default.
- W2801841898 hasRelatedWork W2147326489 @default.
- W2801841898 hasRelatedWork W2473936127 @default.
- W2801841898 hasRelatedWork W2520394128 @default.
- W2801841898 hasRelatedWork W2598952789 @default.
- W2801841898 hasRelatedWork W2613744240 @default.
- W2801841898 hasRelatedWork W2735990528 @default.
- W2801841898 hasRelatedWork W2754055835 @default.
- W2801841898 hasRelatedWork W2774813701 @default.
- W2801841898 hasRelatedWork W2781547231 @default.
- W2801841898 hasRelatedWork W2891551044 @default.
- W2801841898 hasRelatedWork W2904484224 @default.
- W2801841898 hasRelatedWork W3005355765 @default.
- W2801841898 hasRelatedWork W3097313111 @default.
- W2801841898 hasRelatedWork W3129592104 @default.
- W2801841898 hasRelatedWork W3175106610 @default.
- W2801841898 isParatext "false" @default.
- W2801841898 isRetracted "false" @default.
- W2801841898 magId "2801841898" @default.
- W2801841898 workType "article" @default.